男性乳腺癌特征分析:EORTC 10085/TBCRC/BIG/NABCG国际男性乳腺癌项目第一部分结果
该研究对1990-2010年间93个中心/9个国家的1483例男性乳腺癌患者进行回顾性分析,中位年龄68.4岁。多数肿瘤为ER/PR/AR阳性、Luminal B-like/HER2阴性,ER、PR、AR高表达与更好的OS和RFS相关,而分级、Ki67和IHC亚型无关联。随时间推移年龄校正的乳腺癌死亡率显著改善。
要点
- 男性乳腺癌通常ER、PR、AR阳性,Luminal B-like/HER2阴性。
- ER、PR、AR高表达与更好的OS和RFS相关,分级、Ki67和IHC亚型无关联。
- 56%患者为T1肿瘤但仅4%接受保乳手术,仅77%接受辅助内分泌治疗。
核心结论
- 男性乳腺癌通常为ER、PR、AR阳性且Luminal B-like/HER2阴性,ER、PR、AR高表达与更好的OS和RFS相关,而分级、Ki67和IHC亚型与生存无关联。
- 随时间推移观察到年龄校正的乳腺癌死亡率显著改善。
研究设计与样本
- 回顾性联合分析,纳入1990-2010年间93个中心/9个国家的男性乳腺癌患者,要求有随访和肿瘤样本,样本在三个中心实验室统一分析。
- 共1822例入组,1483例纳入分析;63.5%于2001-2010年诊断;57例(5.1%)为转移性疾病(M1)。
- 中位诊断年龄68.4岁;M0患者中位随访7.2年(0.0-23.2),M1患者2.6年(0.0-12.7)。
主要发现
- M0患者中56.2%为淋巴结阴性(N0),48.5%为T1肿瘤;4%接受保乳手术,18%接受前哨淋巴结活检;半数接受辅助放疗,29.8%接受(新)辅助化疗,76.8%接受辅助内分泌治疗(其中88.4%为他莫昔芬)。
- 中心病理显示M0肿瘤中84.8%为浸润性导管癌,51.5%为2级;99.3% ER阳性,81.9% PR阳性,96.9% AR阳性(Allred评分≥3);61.1% Ki67低表达(<14%阳性细胞)。
- IHC替代分型:41.9% Luminal-A-like,48.6% Luminal-B-like/HER2阴性,8.7% HER2阳性,0.3%三阴性。
- 高ER表达(P=0.001)、高PR表达(P=0.002)、高AR表达(P=0.019)与更好的OS和RFS相关;OS/RFS与HER2状态、Ki67、IHC亚型及分级无关联。
- 50岁以下男性乳腺癌特异性死亡率更高。
关键数值与推荐
- ER、PR、AR阳性判定为Allred评分≥3;Ki67低表达定义为<14%阳性细胞。
- ER高表达与OS/RFS改善相关(P=0.001),PR高表达相关(P=0.002),AR高表达相关(P=0.019)。
临床怎么用
- 男性乳腺癌应常规检测ER、PR、AR,高表达提示预后较好。
- 尽管T1肿瘤比例高,保乳手术率仅4%,辅助内分泌治疗率仅77%,提示需优化局部治疗和内分泌治疗的应用。
- 分级、Ki67和IHC亚型对男性乳腺癌预后判断价值有限,不应作为主要决策依据。
局限性
- 回顾性研究设计,可能存在选择偏倚和信息偏倚。
- 仅纳入有随访和肿瘤样本的患者,可能不代表全部男性乳腺癌人群。
- 样本来自93个中心/9个国家,治疗模式和病理评估可能存在异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Male breast cancer (BC) is rare, managed by extrapolation from female BC. The International Male BC Program aims to better characterize and manage this disease. We report the results of part I, a retrospective joint analysis of cases diagnosed during a 20-year period. METHODS: Patients with follow-up and tumor samples, treated between 1990 and 2010, in 93 centers/9 countries. Samples were centrally analyzed in three laboratories (the United Kingdom, the Netherlands and the United States). RESULTS: Of 1822 patients enrolled, 1483 were analyzed; 63.5% were diagnosed between 2001 and 2010, 57 (5.1%) had metastatic disease (M1). Median age at diagnosis: 68.4 years. Of 1054 M0 cases, 56.2% were node-negative (N0) and 48.5% had T1 tumors; 4% had breast conserving surgery (BCS), 18% sentinel lymph-node biopsy; half received adjuvant radiotherapy; 29.8% (neo)adjuvant chemotherapy and 76.8% adjuvant endocrine therapy (ET), mostly tamoxifen (88.4%). Per central pathology, for M0 tumors: 84.8% ductal invasive carcinomas, 51.5% grade 2; 99.3% estrogen receptor (ER)-positive; 81.9% progesterone receptor (PR)-positive; 96.9% androgen receptor (AR)-positive [ER, PR or AR Allred score ≥3]; 61.1% Ki67 expression low (<14% positive cells); using immunohistochemistry (IHC) surrogates, 41.9% were Luminal-A-like, 48.6% Luminal-B-like/HER-2-negative, 8.7% HER-2-positive, 0.3% triple negative. Median follow-up: 8.2 years (0.0-23.8) for all, 7.2 years (0.0-23.2), for M0, 2.6 years (0.0-12.7) for M1 patients. A significant improvement over time was observed in age-corrected BC mortality. BC-specific-mortality was higher for men younger than 50 years. Better overall (OS) and recurrence-free survival (RFS) were observed for highly ER+ (P = 0.001), highly PR+ (P = 0.002), highly AR+ disease (P = 0.019). There was no association between OS/RFS and HER-2 status, Ki67, IHC subtypes nor grade. CONCLUSIONS: Male BC is usually ER, PR and AR-positive, Luminal B-like/HER2-negative. Of note, 56% patients had T1 tumors but only 4% had BCS. ER was highly positive in >90% of cases but only 77% received adjuvant ET. ER, PR and AR were associated with OS and RFS, whereas grade, Ki67 and IHC surrogates were not. Significant improvement in survival over time was observed.
引用
- Cardoso F, Bartlett JMS, Slaets L, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2018. PMID: 29092024. doi:10.1093/annonc/mdx651
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。